CERo Therapeutics (CERO) SC 13G/A PHOENIX BIOTECH ACQUISITION / CANTOR FITZGERALD SECURITIES ownership change

EXHIBIT 99.1

JOINT FILING AGREEMENT

Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13G to which this Agreement is attached as an Exhibit, and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. This Agreement may be executed in one or more counterparts.

Date: February 14, 2022

CANTOR FITZGERALD SECURITIES
By:	/s/ Howard W. Lutnick
	Name: Howard W. Lutnick
	Title:   Chief Executive Officer
CANTOR FITZGERALD & CO.
By:	/s/ Howard W. Lutnick
	Name: Howard W. Lutnick
	Title:   Chief Executive Officer
CANTOR FITZGERALD, L.P.
By:	/s/ Howard W. Lutnick
	Name: Howard W. Lutnick
	Title:   Chief Executive Officer
CF GROUP MANAGEMENT, INC.
By:	/s/ Howard W. Lutnick
	Name: Howard W. Lutnick
	Title:   Chief Executive Officer
By:	/s/ Howard W. Lutnick
	Howard W. Lutnick

[Schedule 13G/A Amendment 1 – Phoenix Biotech Acquisition Corp. – Joint Filing Agreement – February 2022]